Efficacy and safety of Bruton’s tyrosine kinase inhibitors compared to Teriflunomide in relapsing multiple sclerosis: A systematic review and meta-analysis
Compared with teriflunomide, BTK inhibitors were associated with a reduced risk of short-term disability progression, whereas no differences were observed in relapse rates, MRI activity, or safety outcomes.
Authors
- Helen Michaela de Oliveira (ORCID: https://orcid.org/0000-0003-0061-7492)
- Milene Vitória Sampaio Sobral (ORCID: https://orcid.org/0009-0001-5754-6472)
- Thales Pardini Fagundes (ORCID: https://orcid.org/0000-0002-3302-9913)
- Altair Pereira De Melo Neto
Institutions
- Universidade de São Paulo (BR)
- Universidade Federal de Mato Grosso (BR)
- Universidade do Oeste Paulista (BR)
- Universidade Federal de Roraima (BR)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1016/j.msard.2026.106974
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00